---
title: "Lunai Bioworks (LNAI) news: reverse split and delisting"
url: "https://aibio.space/companies/lunai-bioworks/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "LNAI reverse split, delisting, Nasdaq notice and lawsuit news: Lunai Bioworks receives Nasdaq delisting determination over minimum bid price, requests…"
---

LNAI Lunai Bioworks Inc. NASDAQ · United States

# Lunai Bioworks (LNAI) news LNAI reverse split, delisting and Nasdaq notice news

Listings · 2026-10-23

## [Lunai Bioworks gets Nasdaq delisting notice and plans to leave the exchange](https://aibio.space/news/lunai-bioworks-gets-nasdaq-delisting-notice-plans-leave-exchange/)

Lunai Bioworks will not appeal a Nasdaq staff decision to delist its stock and plans to deregister with the SEC. Trading on Nasdaq is expected to be suspended on October 30, 2026.

## Latest Lunai Bioworks news

1. 2026-10-13 Legal [Weird Science demands $10 million to end Delaware Chancery suit and other claims against Lunai](https://aibio.space/news/weird-science-demands-10-million-end-delaware-chancery-suit-other/) Lunai's 10-K says the Oct 7 demand covers all pending litigation. The Chancery case alleges breach of a 2018 investor rights agreement, and mediation has not been scheduled.
2. 2026-10-09 Legal [Lunai Bioworks cites its Delaware suit against Seven Points Capital in Nasdaq trading halt request](https://aibio.space/news/lunai-bioworks-cites-delaware-suit-against-seven-points-capital-nasdaq/) Lunai's 8-K asks Nasdaq to suspend trading, citing records from its Delaware suit. A later 8-K says trading will be suspended on October 30 unless the company asks for a hearing, and it does not plan to ask.
3. 2026-09-29 Distress [Lunai Bioworks delays annual report, expects net loss of about $3.2 million](https://aibio.space/news/lunai-bioworks-delays-annual-report-expects-net-loss-about-3-2-million/) The company, formerly Renovaro Inc., expects to file its Form 10-K for the year ended June 30, 2026 within the 15-day grace period. Its net loss for the prior year was about $178.0 million.
4. 2026-02-12 Listings [Lunai Bioworks receives Nasdaq delisting determination over minimum bid price, requests hearing](https://aibio.space/news/lunai-bioworks-receives-nasdaq-delisting-determination-minimum-bid/) Nasdaq staff decided on February 6, 2026 to delist Lunai Bioworks, saying a reverse stock split in September 2025 bars the company from the usual 180-day cure period. The company has asked for a hearing, which pauses a February 18 trading suspension.
5. 2025-10-30 Listings [Lunai Bioworks gets Nasdaq deficiency notice on $35 million market value requirement](https://aibio.space/news/lunai-bioworks-gets-nasdaq-deficiency-notice-35-million-market-value/) Lunai Bioworks received a Nasdaq notice that its market value of listed securities had been below the $35 million minimum for 30 consecutive business days. It has until April 27, 2026 to regain compliance, and the company says the notice has no immediate effect on trading.
6. 2025-01-07 Mergers [Renovaro (now Lunai Bioworks) signs binding letter to buy Predictive Oncology](https://aibio.space/news/renovaro-now-lunai-bioworks-signs-binding-letter-buy-predictive/) Renovaro plans to pay for Predictive Oncology with preferred stock in an all-stock deal. The letter of intent sets out the main terms, and the release gives no exchange ratio or value for the shares.

## Lunai Bioworks at a glance

- **Ticker**: LNAI

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $1.7 million

### Related companies

- [60 Degrees Pharmaceuticals](https://aibio.space/companies/60-degrees-pharmaceuticals/) NASDAQ: SXTP
- [OS Therapies](https://aibio.space/companies/os-therapies/) AMEX: OSTX
- [Microbot Medical](https://aibio.space/companies/microbot-medical/) NASDAQ: MBOT
- [Unicycive Therapeutics](https://aibio.space/companies/unicycive-therapeutics/) NASDAQ: UNCY
- [Nascent Biotech](https://aibio.space/companies/nascent-biotech/) OTC: NBIO
- [Edgewise Therapeutics](https://aibio.space/companies/edgewise-therapeutics/) NASDAQ: EWTX
- [Carisma Therapeutics](https://aibio.space/companies/carisma-therapeutics/) OTC: CARM
- [Vir Biotechnology](https://aibio.space/companies/vir-biotechnology/) NASDAQ: VIR

### Also on NASDAQ

- [PACIFIC BIOSCIENCES OF CALIFORNIA, INC.](https://aibio.space/companies/pacific-biosciences-of-california/) PACB
- [CASTLE BIOSCIENCES INC](https://aibio.space/companies/castle-biosciences/) CSTL
- [TransMedics Group](https://aibio.space/companies/transmedics/) TMDX
- [Aclarion](https://aibio.space/companies/aclarion/) ACON
- [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) ZVRA
- [Cuprina Holdings (Cayman)](https://aibio.space/companies/cuprina-cayman/) CUPR

## What Lunai Bioworks does

Lunai Bioworks Inc. is an AI-driven biotechnology company focused on precision medicine, biomarker discovery and therapeutic development for CNS disorders, biodefense and other serious diseases. It operates principally through two subsidiaries, Renovaro Biosciences and BioSymetrics. Renovaro Biosciences intends, if the necessary funding is obtained, to develop allogeneic cell and gene therapies for certain cancers and for serious infectious diseases such as HIV. Its focus areas include RENB-DC11, a genetically modified allogeneic dendritic cell therapeutic vaccine for solid tumors, specifically pancreatic tumors, and RENB-DC20, a similar vaccine for triple negative breast cancer. BioSymetrics is a biomedical artificial intelligence company that integrates genomics, imaging, electronic health records and other real-world evidence to advance biomarker discovery and precision medicine. Its platform uses machine learning pipelines and a proprietary knowledge graph, and it collaborates with pharmaceutical companies, healthcare providers and academic institutions. A third subsidiary, Lunai Bioworks IP, Inc., holds intellectual property from the May 2026 Neurobridge acquisition, including the N2B intranasal drug delivery platform. The filing also says GEDi Cube B.V. filed for bankruptcy and ceased operations during the quarter ended September 30, 2025.

| Product or program | What it is | Stage |
|---|---|---|
| RENB-DC11 | Genetically modified allogeneic dendritic cell vaccine for pancreatic tumors | completed pre-IND, IND-enabling phase |
| RENB-DC20 | Genetically modified allogeneic dendritic cell vaccine for triple negative breast cancer |  |
| N2B intranasal drug delivery platform | Intranasal drug delivery platform held by Lunai Bioworks IP, Inc. |  |
| BioSymetrics AI platform | Machine learning platform for biomarker discovery and precision medicine |  |

Summarised from the company's [10-K filed Oct 13, 2026](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/e7993_10k.htm).

## Lunai Bioworks annual financials

| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Revenue | [$51,992](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/) |  |
| Research and development | [$24,518](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/) | [$537,428](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/) |
| Net income (loss) | [-$3.6 million](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/) | [-$178.0 million](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/) |
| Cash from operations | [-$5.3 million](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/) | [-$7.9 million](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/) |
| Cash and equivalents | [$1.7 million](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/) | [$92,700](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/) |

Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $1.7 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Lunai Bioworks

Did Lunai Bioworks do a reverse stock split?

Our latest story on this, dated Feb 12, 2026: "Lunai Bioworks receives Nasdaq delisting determination over minimum bid price, requests hearing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lunai-bioworks-receives-nasdaq-delisting-determination-minimum-bid/).

Was Lunai Bioworks delisted?

Our latest story on this, dated Oct 23, 2026: "Lunai Bioworks gets Nasdaq delisting notice and plans to leave the exchange". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lunai-bioworks-gets-nasdaq-delisting-notice-plans-leave-exchange/).

Has Lunai Bioworks received a Nasdaq deficiency notice?

Our latest story on this, dated Oct 30, 2025: "Lunai Bioworks gets Nasdaq deficiency notice on $35 million market value requirement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lunai-bioworks-gets-nasdaq-deficiency-notice-35-million-market-value/).

Is Lunai Bioworks involved in a lawsuit?

Our latest story on this, dated Oct 13, 2026: "Weird Science demands $10 million to end Delaware Chancery suit and other claims against Lunai". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/weird-science-demands-10-million-end-delaware-chancery-suit-other/).

What is the ticker symbol of Lunai Bioworks?

Lunai Bioworks Inc. trades under the ticker LNAI on NASDAQ.

Where is Lunai Bioworks listed?

Lunai Bioworks Inc. is listed on NASDAQ.

What is the SEC CIK of Lunai Bioworks?

The SEC Central Index Key (CIK) for Lunai Bioworks Inc. is 1527728. Its filings are on SEC EDGAR.

How many shares does Lunai Bioworks have outstanding?

5,034,452 shares as of 2026-10-13, per the cover page of its 10-K filed 2026-10-13.

Which country or territory is Lunai Bioworks listed under?

Our directory records Lunai Bioworks Inc. under United States.

What does Lunai Bioworks do?

Our directory classifies Lunai Bioworks Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Lunai Bioworks?

The ISIN recorded for Lunai Bioworks Inc. is US29350E3027.

Does aibio.space cover Lunai Bioworks?

aibio.space lists Lunai Bioworks Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Lunai Bioworks incorporated?

SEC records list its state or country of incorporation as DE.

What does Lunai Bioworks develop?

Lunai Bioworks Inc. is an AI-driven biotechnology company focused on precision medicine, biomarker discovery and therapeutic development for CNS disorders, biodefense and other serious diseases. It operates principally through two subsidiaries, Renovaro Biosciences and BioSymetrics.

What is RENB-DC11 from Lunai Bioworks?

RENB-DC11: Genetically modified allogeneic dendritic cell vaccine for pancreatic tumors Stage: completed pre-IND, IND-enabling phase.

## Investor discussion: Lunai Bioworks

Members talk about Lunai Bioworks (LNAI). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Lunai Bioworks, newest first. Each line links the filing it comes from.

1. 2026-10-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001362/e8019_ex99-1.htm)
2. 2026-10-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/e7993_10k.htm)
3. 2026-10-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/e7993_10k.htm)
4. 2026-09-29 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001299/e7978_nt10-k.htm)
5. 2026-06-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000865/e7720_8-k.htm)
6. 2026-05-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000759/e7662_ex99-1.htm)
7. 2026-05-13 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000718/e7639_8-k.htm)
8. 2026-05-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.01,3.01,3.02,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/e7595_8k.htm)
9. 2026-04-28 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000623/e7584_ex99-1.htm)
10. 2026-04-13 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000559/e7555_def14a.htm)
11. 2026-04-02 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000528/e7522_pre14a.htm)
12. 2026-03-30 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/e7507_ex99-1.htm)
13. 2026-02-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000282/e7360_8-k.htm)
14. 2026-02-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/e7323_8-k.htm)
15. 2025-11-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225001495/e7011_8-k.htm)
16. 2025-10-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225001446/e6985_8-k.htm)
17. 2025-10-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225001399/e6960_ex99-1.htm)
18. 2025-09-29 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225001316/e6882_10-k.htm)
19. 2025-09-29 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225001316/e6882_10-k.htm)
20. 2025-09-24 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225001297/e6874_ex99-1.htm)
21. 2025-09-05 Distress Reported a material impairment charge. SEC Form 8-K (Items 2.06,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225001204/e6829_8-k.htm)
22. 2025-08-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225001076/e6758_8k.htm)
23. 2025-07-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225001053/e6746_def14a.htm)
24. 2025-07-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225000995/e6710_pre14a.htm)
25. 2025-07-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225000971/e6700_8-k.htm)
26. 2025-07-09 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225000948/e6687_ex99-1.htm)
27. 2025-04-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225000592/e6530_8-k.htm)
28. 2025-04-10 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225000562/e6512_8k.htm)
29. 2025-02-19 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225000248/e6373_8k.htm)
30. 2025-02-18 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1527728/000173112225000241/e6370_nt-10q.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LNAI on TradingView](https://www.tradingview.com/symbols/NASDAQ-LNAI/).

## SEC filings and registration

- **SEC name**: Lunai Bioworks Inc.

- **CIK**: 1527728

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: LNAI (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: June 30

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES, CA, 90067

- **Phone**: 45 39179840

- **Shares outstanding**: 5,034,452 as of 2026-10-13 (10-K filed 2026-10-13)

- **Former names**: RENOVARO INC.; RENOVARO BIOSCIENCES INC.; Enochian Biosciences Inc

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-K](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001339/e7993_10k.htm) filed 2026-10-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1527728/000173112226001333/e8001_8k.htm) filed 2026-10-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000871/e7731_8k.htm) filed 2026-06-17
- [8-K](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000865/e7720_8-k.htm) filed 2026-06-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000759/e7662_8-k.htm) filed 2026-05-20
- [10-Q](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000749/e7638_10-q.htm) filed 2026-05-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000718/e7639_8-k.htm) filed 2026-05-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/e7595_8k.htm) filed 2026-05-01

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001527728), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Lunai Bioworks Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LNAI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Lunai Bioworks Inc.

- **Ticker**: LNAI

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US29350E3027

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LNAI/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/lunai-bioworks/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lunai Bioworks (LNAI) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/lunai-bioworks/